Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Lifecare ASA is a medical sensor company based in Bergen, Norway, specializing in the development of miniaturized and implantable nanobiosensors for continuous monitoring of glucose and other biomarkers in the human body and in pets. The company's primary focus is on next-generation continuous glucose monitoring (CGM) systems, leveraging osmotic pressure as a sensing principle to enable accurate, long-term detection of various body analytes. Key products include Sencell, a micro sensor designed for glucose level monitoring in diabetes patients and veterinary applications, as well as a nanostrain biosensor that measures pressure, temperature, force, and other indicators in live tissue. Lifecare ASA also develops medical devices for the removal of subdermal implants. Operating in the healthcare and biotechnology sectors, particularly medical devices, the company contributes to improved diabetes management and personalized health monitoring solutions for both human and animal care through its innovative sensor technology.
€0.03
+€0.00 (+0.00%)
EOD Jul 2, 2026
The business is unprofitable at the operating level (-116035.71% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 96.3% YoY. Margins deteriorated 113238.6pp alongside, both lines moving the wrong way.
ROIC dropped from -83.38% to -112.82%, capital efficiency is deteriorating. Negative free cash flow of -NOK 117M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
NOK 107K
▼ -96.3% YoY
Net Income (TTM)
-NOK 136M
▼ -65.2% YoY
Op. Margin
-116275.70%
▼ -113238.6pp YoY
ROIC
-112.82%
▼ -29.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-NOK 122M
▼ -49.2% YoY
Op. Cash Flow (TTM)
-NOK 91M
▼ -56.6% YoY
Net Debt
NOK 92M
Cash & Equiv.
NOK 5M
3Y CAGR: -74.5%
Continue Research
Lifecare ASA (LIFE.XOSL)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Lifecare ASA scores 0/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Lifecare ASA scores 0 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -116,275.7% operating margin and a -112.8% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh LIFE.XOSL's valuation and scores 0/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.